RayKnowChina Research Map
Shortlist0

Not yet recruitingNeuromyelitis optica spectrum disorderPhase not stated

Registered title, quoted from ClinicalTrials.gov

Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Xiamen Hospital; 3 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorXiamen Hospital厦门市中医院XiamenHospital page
  2. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  3. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
  4. Study siteZhongshan Hospital, Xiamen University厦门大学附属中山医院XiamenHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07266051, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07266051, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria Inclusion Criteria for the NMOSD Patient Group

  • Aged 18 years or older, regardless of sex
  • Fulfilled the diagnostic criteria for Neuromyelitis Optica Spectrum Disorders as defined by the 2021 Chinese guidelines for the diagnosis and management of NMOSD
  • Seropositive for AQP4-IgG
  • Provided informed consent by the participant or their legal guardian

Inclusion Criteria for the Healthy Control Group

  • Aged 18 years or older, regardless of sex
  • Gender- and age-matched healthy individuals
  • Provided informed consent by the participant or their legal guardian

Exclusion Criteria

  • Diagnosis of other serious systemic diseases (e.g., malignancy)
  • Presence of severe psychiatric disorders that would preclude compliance with study procedures and/or follow-up assessments
  • History of infectious pathologies of the central nervous system
  • Those with severe liver and kidney function impairment or dysfunction of other vital organs
  • Patients with other conditions that do not allow participation in clinical research
  • Patients allergic to gadolinium-DPTA
  • Patients with other conditions that do not allow participation in clinical research

Quoted from ClinicalTrials.gov, NCT07266051, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07266051, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07266051